Lycopene decision delayed
This article was originally published in The Tan Sheet
FDA will not issue a decision before April 12 on a health claim stating lycopene is an "effective modifier of the risk of certain cancers," law firm Emord & Associates states Feb. 10. The agency was supposed to respond to the petition Dec. 24. Emord filed the petition on behalf of American Longevity in June 2003 (1"The Tan Sheet" June 9, 2003, p. 17)...
You may also be interested in...
There is significant scientific agreement among experts that lycopene is an "effective modifier of the risk of certain cancers," supplement marketer American Longevity states in a June 4 health claim petition to FDA
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.